PrintBio

Executive Summary

PrintBio, founded in 2021 and headquartered in San Francisco, is a synthetic biology company developing advanced 3D-printed surgical meshes for soft tissue repair. In collaboration with leading surgeons, the company has created a two-brand portfolio: DynaFlex™ Programmable Surgical Mesh (PSM) and DynaForm™ PSM. These products offer broad customizability to meet diverse clinical needs, with DynaFlex™ PSM specifically designed to empower surgeons with enhanced flexibility and performance in complex repairs. The programmable nature of the meshes allows for patient-specific tailoring, potentially improving surgical outcomes and reducing complications. PrintBio's technology leverages proprietary 3D printing techniques to produce biodegradable or permanent scaffolds that integrate with the body's tissue, addressing a significant market in hernia repair, pelvic organ prolapse, and other soft tissue reconstructions. The soft tissue repair market, valued at over $5 billion globally, is dominated by traditional synthetic meshes with known limitations such as infection, adhesion, and lack of customization. PrintBio's programmable meshes aim to overcome these challenges by enabling on-demand manufacturing of implants with precise mechanical properties and degradation profiles. The company is currently in the pre-revenue stage, with its products not yet FDA-cleared. Key upcoming catalysts include FDA clearance decisions, clinical trial initiations, and potential strategic partnerships. If successful, PrintBio could disrupt the surgical mesh market by offering a new standard of personalized care. However, regulatory hurdles and manufacturing scale-up remain risks.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for DynaFlex PSM60% success
• Q1 2027Initiation of Pivotal Clinical Trial for DynaForm PSM70% success
• H2 2026Strategic Partnership or Licensing Agreement with a Major Medical Device Company30% success